Core Insights - Transcenta Holding Limited has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc to enhance biopharmaceutical manufacturing capabilities [1][2] Group 1: Collaboration Details - Transcenta will grant EirGenix a non-exclusive license to utilize its Highly Intensified Continuous Bioprocessing (HiCB) platform, which includes advanced continuous perfusion and hybrid continuous purification technologies [2][3] - The agreement includes substantial upfront and milestone payments, as well as future royalty payments based on the commercial use of the licensed technologies, indicating expected long-term value creation for both companies [2] Group 2: Technology and Benefits - The HiCB platform aims to improve process efficiency, control, and product consistency while significantly reducing the cost of goods compared to traditional fed-batch manufacturing processes, thereby enhancing global patient access to affordable biologics [3] - EirGenix plans to implement the HiCB platform to support its biologics development programs and manufacturing operations, particularly for clients seeking intensified and continuous manufacturing solutions [4] Group 3: Leadership Perspectives - Transcenta's leadership emphasizes the importance of the HiCB platform in transforming biologics manufacturing and aims to reinvest proceeds from collaborations to strengthen its technology and R&D pipeline [5] - EirGenix's leadership highlights the partnership as a win-win situation that combines Transcenta's innovation with EirGenix's expertise, aiming for more efficient and sustainable biologics production [5] Group 4: Company Background - Transcenta is a global clinical stage biopharmaceutical company with integrated capabilities in antibody-based biotherapeutics, with facilities in Suzhou and Hangzhou, and clinical development centers in China, the U.S., and Europe [6][7] - EirGenix is Taiwan's largest biologics CDMO, providing comprehensive services from cell line and process development to GMP manufacturing, and is also advancing its own biosimilar and ADC pipeline [8]
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics